Ipamorelin — a selective GH secretagogue in the research literature

Ipamorelin is a synthetic pentapeptide belonging to the class of growth hormone secretagogues (GH secretagogues). In the preclinical literature it drew attention as one of the most selective compounds of this class: in animal models it stimulated the release of GH from the pituitary while producing minimal impact on cortisol and prolactin secretion. It is precisely this "cleanness" of action — stimulation of the somatotropic axis without a diffuse effect on other pituitary hormones — that made ipamorelin a valued research tool for the isolated study of a single signaling pathway. Peptides here act as protein fragments serving as signaling molecules, and the specificity of ipamorelin is closer to the precision of a screwdriver than a hammer.

Mechanism in brief

Ipamorelin acts as an agonist of the growth hormone secretagogue receptor (GHS-R1a) — the same receptor through which endogenous ghrelin acts. In the "lock and key" model the ipamorelin molecule serves as a key fitted to the lock that is GHS-R1a on the somatotropic cells of the pituitary. Binding of the receptor triggers an intracellular pathway leading to the release of stored GH. Unlike analogs of GHRH (growth hormone-releasing hormone), which act through a separate GHRH receptor, ipamorelin mimics ghrelin — which is why in the literature both classes are described as complementary pathways of the same neuroendocrine axis.

What is being studied

• Selective stimulation of the GH axis. In animal models (including rodents and pigs) ipamorelin was studied as a compound inducing the release of growth hormone from pituitary somatotrophs via the GHS-R1a receptor. The kinetics and magnitude of this release compared with other secretagogues were the subject of analysis.
• Hormonal selectivity profile. In preclinical studies in animal models the effect of ipamorelin on the secretion of ACTH, cortisol and prolactin was compared against older peptides of this group. The literature describes ipamorelin as a compound with a distinctly narrower profile — this is the main reason for its use as a "tool" for pure stimulation of the somatotropic axis.
• Bone metabolism. In animal models, GH secretagogues, including ipamorelin, were studied in the context of bone tissue parameters and the GH/IGF-1 axis. These are preclinical data concerning physiological processes, not effects in humans.
• Gastrointestinal motility. Because the ghrelin receptor (GHS-R1a) participates in the regulation of gastrointestinal motility, agonists of this receptor — including ipamorelin — were studied in animal models and early research on peristalsis as a tool for probing the ghrelin pathway in the gastrointestinal tract.

All of the above areas describe processes in specific experimental models and receptor pathways — they do not constitute a description of action in humans.

Origin and historical context

Ipamorelin was characterized in the late 1990s by a team of researchers associated with Novo Nordisk; the key pharmacological paper by Raun and co-workers appeared in the European Journal of Endocrinology in 1998, describing it as the first selective growth hormone secretagogue. The compound arose from the search for synthetic peptides with a narrower profile than earlier molecules of this class, such as GHRP-6 or GHRP-2, which in animal models more strongly stimulated cortisol and prolactin secretion as well. In subsequent years ipamorelin remained a reference point in comparative studies on the selectivity of ghrelin receptor agonists.

Research specification

Ipamorelin is supplied as a lyophilisate (powder after lyophilization), which is the standard form of research peptides owing to stability in transport and storage. In a laboratory context, material in lyophilisate form is usually stored away from light, moisture and elevated temperature. The quality standard for research material is confirmation of purity by HPLC and mass identification by mass spectrometry, documented in a certificate of analysis (COA). Analytical parameters and data sheets for individual compounds can be found in the safety data sheets section. These data describe the quality and identity of the substance and do not constitute any health claims.

Level of evidence

The available knowledge about ipamorelin rests primarily on in vitro studies and on animal models (chiefly preclinical). Data from human studies are limited and do not allow the formulation of conclusions extending beyond the research context. Many of the observed relationships — the selectivity profile, GH release kinetics, interactions with the ghrelin pathway — require further study, including confirmation in larger and better-controlled systems. Ipamorelin should be regarded as a reference compound in research on the somatotropic axis, not as a substance with an established profile of action in humans.

For research purposes only. Not for consumption by humans or animals.